Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9782551
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
US9782550
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
US10918816
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(13 years from now) | |
US10569034 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10208307 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(13 years from now) | |
US11286486 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(13 years from now) | |
US10683501 | ALNYLAM PHARMS INC | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 13, 2027 |
Drugs and Companies using VUTRISIRAN ingredient
NCE-1 date: June, 2026
Market Authorisation Date: 13 June, 2022
Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9782550
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
US9782551
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Feb, 2036
(13 years from now) | |
US10918816
(Pediatric) | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Jun, 2036
(13 years from now) | |
US10569034 | TEVA PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10959996 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
US11357772 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
US11446291 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(13 years from now) | |
US10959996
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) | |
US11357772
(Pediatric) | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
New Chemical Entity Exclusivity (NCE) | Apr 3, 2022 |
M | Jun 24, 2024 |
Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: October, 2023
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10898482 | JANSSEN BIOTECH | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 12, 2024 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic, surgically unresectable urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 genetic alterations and progressed during or following prior platinum-containing chemotherapy; Treatment of adults with locally advanced or metastatic urothelial carcinoma that has susceptible fgfr3 or fgfr2 genetic alterations and progressed during or following prior platinum-containing chemotherapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10213487 | ELI LILLY AND CO | Nasal powder formulation for treatment of hypoglycemia |
Feb, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jul 24, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 24 July, 2019
Treatment: Treatment of severe hypoglycemia in patients with diabetes
Dosage: POWDER;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10548846 | GILEAD SCIENCES INC | Therapeutic compositions for treatment of human immunodeficiency virus |
Nov, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 18, 2026 |
New Chemical Entity Exclusivity (NCE) | Feb 7, 2023 |
New Patient Population (NPP) | Jun 18, 2022 |
M | Feb 24, 2024 |
NCE-1 date: February, 2022
Market Authorisation Date: 07 February, 2018
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10300065 | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jan, 2036
(12 years from now) | |
US10300065
(Pediatric) | ASTRAZENECA | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Nov 5, 2023 |
M | May 9, 2025 |
Pediatric Exclusivity (PED) | Nov 28, 2023 |
Drugs and Companies using TICAGRELOR ingredient
Market Authorisation Date: 20 July, 2011
Treatment: Reducing the rate of cardiovascular death, myocardial infarction (mi), and stroke in a patient receiving 75-100 mg aspirin daily with a history of mi by administering 60 mg ticagrelor twice daily; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspirin daily and having or who had acute coronary syndrome by administering 60 mg ticagrelor twice daily
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9796721 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10167291 | ASTRAZENECA | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 21, 2026 |
New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
New Indication (I) | Nov 21, 2022 |
Drugs and Companies using ACALABRUTINIB ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 31 October, 2017
Treatment: Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11059829 | ASTRAZENECA | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 31, 2022 |
Drugs and Companies using ACALABRUTINIB MALEATE ingredient
NCE-1 date: October, 2021
Market Authorisation Date: 03 August, 2022
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic leukemia; Treatment of adult patients with previously untreated small lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination with obinutuzumab; Treatment of adult patients with small lymphocytic leukemia; Treatment of adult patients with chronic lymphocytic leukemia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10493083 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US11395828 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US11389461 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US10624906 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US10888570 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US9757394 | CMP DEV LLC | Spironolactone aqueous formulations |
Oct, 2036
(13 years from now) | |
US10660907 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) | |
US11491166 | CMP DEV LLC | Spironolactone aqueous compositions |
Oct, 2036
(13 years from now) |
Drugs and Companies using SPIRONOLACTONE ingredient
Market Authorisation Date: 04 August, 2017
Treatment: Carospir is indicated for treatment of nyha class iii-iv heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure; Carospir is indicated as an add-on therapy for the treatment of hypertension, to lower blood pressure in adult patients who are not adequately controlled on other agents; Carospir is indicated for the management of edema in adult cirrhotic patients when edema is not responsive to fluid and sodium restriction
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10478400 | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Jun, 2036
(13 years from now) | |
US11254649 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Jun, 2036
(13 years from now) | |
US10590102 | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Jun, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10478400
(Pediatric) | GENENTECH INC | Immediate-release tablets containing combimetinib and methods of making and using the same |
Dec, 2036
(13 years from now) | |
US11254649
(Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone |
Dec, 2036
(13 years from now) | |
US10590102
(Pediatric) | GENENTECH INC | Crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]methanone |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 10, 2022 |
New Indication (I) | Oct 28, 2025 |
M | Jul 28, 2025 |
Pediatric Exclusivity (PED) | Jan 28, 2026 |
Drugs and Companies using COBIMETINIB FUMARATE ingredient
Market Authorisation Date: 10 November, 2015
Treatment: Method of using cobimetinib for the treatment of melanoma
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10993952 | INGENUS PHARMS LLC | Stable ready to use cyclophosphamide liquid formulations |
Feb, 2036
(13 years from now) |
Drugs and Companies using CYCLOPHOSPHAMIDE ingredient
Market Authorisation Date: 30 July, 2020
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11311620 | PHOTOCURE ASA | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(13 years from now) | |
US10556010 | PHOTOCURE ASA | Neoadjuvant therapy for bladder cancer |
Dec, 2036
(13 years from now) |
Drugs and Companies using HEXAMINOLEVULINATE HYDROCHLORIDE ingredient
Market Authorisation Date: 28 May, 2010
Treatment: Detection of carcinoma in the bladder by photodynamic cystoscopy
Dosage: FOR SOLUTION;INTRAVESICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 21, 2023 |
Orphan Drug Exclusivity (ODE) | Nov 21, 2025 |
Drugs and Companies using GLASDEGIB MALEATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 21 November, 2018
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10842751 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(13 years from now) | |
US10603282 | MSD MERCK CO | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Nov, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 30, 2023 |
New Indication (I) | Sep 19, 2022 |
New Patient Population (NPP) | Jan 27, 2025 |
Drugs and Companies using DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE ingredient
NCE-1 date: August, 2022
Market Authorisation Date: 30 August, 2018
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9717796 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) | |
US9649296 | HQ SPCLT PHARMA | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
Apr, 2036
(13 years from now) |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 October, 2015
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10426787 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(13 years from now) | |
US10251895 | BAUSCH | Topical compositions and methods for treating psoriasis |
Jun, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 25, 2022 |
Drugs and Companies using HALOBETASOL PROPIONATE; TAZAROTENE ingredient
Market Authorisation Date: 25 April, 2019
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: LOTION;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10376527 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US10722456 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US10799517 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US9949990 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US9795620 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) | |
US9572819 | BDSI | Oral composition of celecoxib for treatment of pain |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 5, 2023 |
Drugs and Companies using CELECOXIB ingredient
Market Authorisation Date: 05 May, 2020
Treatment: Acute treatment of migraine with or without aura in adults
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11058667 | NOVARTIS PHARMS CORP | Sacubitril-valsartan dosage regimen for treating heart failure |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Oct 1, 2022 |
M | Feb 16, 2024 |
Pediatric Exclusivity (PED) | Apr 1, 2023 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 07 July, 2015
Treatment: Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10772868 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US9669008 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US10786482 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US10154987 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US9808442 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US10039745 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US11141405 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US11040023 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) | |
US11173141 | AZURITY | Enalapril formulations |
Mar, 2036
(13 years from now) |
Drugs and Companies using ENALAPRIL MALEATE ingredient
Market Authorisation Date: 20 September, 2016
Treatment: Treatment of hypertension; Method of treating left ventricular dysfunction; Method of treating hypertension; Method of treatment of heart failure; Treatment of heart failure
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) |
Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient
Market Authorisation Date: 20 October, 2020
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9849199 | GISKIT | Composition and method for medical imaging of body cavities |
Feb, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 7, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: NA
Dosage: FOAM;INTRAUTERINE
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10413543 | SUN PHARM | Stable multiparticulate pharmaceutical composition of rosuvastatin |
Feb, 2036
(13 years from now) |
Drugs and Companies using ROSUVASTATIN CALCIUM ingredient
Market Authorisation Date: 18 December, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10947183 | ZOGENIX INC | Fenfluramine compositions and methods of preparing the same |
Dec, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10950331
(Pediatric) | ZOGENIX INC | Control system for control of distribution of medication |
Mar, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 25, 2027 |
New Product (NP) | Jun 25, 2023 |
New Indication (I) | Mar 25, 2025 |
Pediatric Exclusivity (PED) | Dec 25, 2027 |
Drugs and Companies using FENFLURAMINE HYDROCHLORIDE ingredient
Market Authorisation Date: 25 June, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10705070 | AADI | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
Mar, 2036
(13 years from now) | |
US10973806 | AADI | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
Jun, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Nov 22, 2024 |
Drugs and Companies using SIROLIMUS ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (pecoma) with a dose between about 56 mg/m2 and about 100 mg/m2 administered on days 1 and 8 of a 21-day cycle
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10030005 | GENENTECH INC | Inhibitors of RET |
Nov, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 4, 2025 |
Orphan Drug Exclusivity (ODE) | Sep 4, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: Treatment of adult patients with metastatic rearranged during transfection (ret) fusion-positive non-small cell lung cancer (nsclc) as detected by an fda approved test; Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate); Treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic ret-mutant medullary thyroid cancer (mtc) who require systemic therapy
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10213572 | VERO BIOTECH | Nitrogen dioxide storage cassette |
Feb, 2036
(13 years from now) |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 20 December, 2019
Treatment: NA
Dosage: GAS;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10383821 | ROMEG | Colchicine drug-to-drug interactions |
Nov, 2036
(13 years from now) | |
US10383820 | ROMEG | Colchicine drug-to-drug interactions |
Nov, 2036
(13 years from now) | |
US9907751 | ROMEG | Composition and method of use of colchicine oral liquid |
Nov, 2036
(13 years from now) |
Drugs and Companies using COLCHICINE ingredient
Market Authorisation Date: 30 January, 2019
Treatment: A method of prophylactic treatment of gout flares in adults comprises administering to a patient a liquid colchicine oral solution
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9649364 | XERIS | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 10, 2022 |
Drugs and Companies using GLUCAGON ingredient
Market Authorisation Date: 10 September, 2019
Treatment: Treatment of severe hypoglycemia
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11065250 | PFIZER | Solid dosage forms of palbociclib |
May, 2036
(13 years from now) |
Drugs and Companies using PALBOCICLIB ingredient
Market Authorisation Date: 01 November, 2019
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10828259 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
US9655857 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
US10010507 | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
US10213386 | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Mar, 2036
(13 years from now) | |
US10213386
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
US10010507
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
US9655857
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) | |
US10828259
(Pediatric) | PHARMACYCLICS INC | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
M | Jan 25, 2022 |
New Patient Population (NPP) | Aug 24, 2025 |
Pediatric Exclusivity (PED) | Feb 24, 2026 |
Drugs and Companies using IBRUTINIB ingredient
Market Authorisation Date: 16 February, 2018
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10851104 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10851103 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10844058 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10065952 | NEUROCRINE | Valbenazine salts and polymorphs thereof |
Oct, 2036
(13 years from now) | |
US10906902 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
US10919892 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) | |
US10906903 | NEUROCRINE | Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 11, 2022 |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
NCE-1 date: April, 2021
Market Authorisation Date: 11 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(13 years from now) | |
US9770570
(Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(13 years from now) |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of providing nitric oxide therapy to a patient by measuring and displaying an indication of the calculated delivery concentration of nitiric oxide as compared to the desired delivery concentration of nitric oxide
Dosage: GAS;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Aug 30, 2024 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 18 May, 2015
Treatment: Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago; Reinitiation of schizophrenia treatment following a missed dose 4-9 months ago
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 13, 2022 |
New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using RIBOCICLIB SUCCINATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 13 March, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Mar 13, 2022 |
New Patient Population (NPP) | Dec 10, 2024 |
Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient
NCE-1 date: March, 2021
Market Authorisation Date: 04 May, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10660904 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(13 years from now) | |
US10166243 | CORCEPT THERAP | Optimizing mifepristone levels for cushing'S patients |
Apr, 2036
(13 years from now) | |
US10166242 | CORCEPT THERAP | Optimizing mifepristone levels for Cushing's patients |
Apr, 2036
(13 years from now) | |
US9943526 | CORCEPT THERAP | Optimizing mifepristone levels for cushing's patients |
Apr, 2036
(13 years from now) | |
US10006924 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent cushing's syndrome |
Aug, 2036
(13 years from now) | |
US10495650 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(13 years from now) | |
US9829495 | CORCEPT THERAP | Method for differentially diagnosing ACTH-dependent Cushing's syndrome |
Aug, 2036
(13 years from now) |
Drugs and Companies using MIFEPRISTONE ingredient
Market Authorisation Date: 17 February, 2012
Treatment: Treating cushing's syndrome
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10449146 | SUNOVION PHARMS INC | Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(13 years from now) | |
US10959943 | SUNOVION PHARMS INC | Methods of treating Parkinson's disease by administration of apomorphine to an oral mucosa |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | May 21, 2023 |
Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 21 May, 2020
Treatment: Treatment of 'off' episodes in patients with parkinson's disease
Dosage: FILM;SUBLINGUAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11077055 | DEXCEL PHARMA | Orally disintegrating compositions |
Apr, 2036
(13 years from now) |
Drugs and Companies using LANSOPRAZOLE ingredient
Market Authorisation Date: 07 June, 2016
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10851377 | NOVARTIS | Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 22, 2026 |
Drugs and Companies using INCLISIRAN SODIUM ingredient
NCE-1 date: December, 2025
Market Authorisation Date: 22 December, 2021
Treatment: As an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (hefh) or clinical atherosclerotic cardiovascular disease (ascvd), by inhibiting expression of the pcsk9 gene
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11154498 | CUSTOPHARM INC | Stabilized liquid formulation of levothyroxine |
Jul, 2036
(13 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 17 May, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11135190 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(13 years from now) | |
US9782376 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(13 years from now) | |
US10398669 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(13 years from now) |
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 11 April, 2019
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11020407 | MAYNE PHARMA | Corticosteroid containing foam compositions and method of manufacture thereof |
Nov, 2036
(13 years from now) | |
US10857159 | MAYNE PHARMA | Halobetasol foam composition and method of use thereof |
Nov, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Aug 18, 2024 |
Drugs and Companies using HALOBETASOL PROPIONATE ingredient
Market Authorisation Date: 24 May, 2018
Treatment: For the topical treatment of plaque psoriasis in patients 18 years of age and older
Dosage: AEROSOL, FOAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10688518 | SUNOVION RESP | Method of manufacturing a vibratable head for an aerosol generator and vibratable head for an aerosol generator |
Nov, 2036
(13 years from now) | |
US10744277 | SUNOVION RESP | Aerosol delivery device and method of operating the aerosol delivery device |
Dec, 2036
(13 years from now) |
Drugs and Companies using GLYCOPYRROLATE ingredient
Market Authorisation Date: 05 December, 2017
Treatment: A method of using an aerosol delivery device to aerosolize glycopyrrolate for the treatment of chronic obstructive pulmonary disease (copd)
Dosage: SOLUTION;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10420749 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11020376 | PFIZER | Crystalline form of lorlatinib free base |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 2, 2023 |
Orphan Drug Exclusivity (ODE) | Mar 3, 2028 |
New Indication (I) | Mar 3, 2024 |
Drugs and Companies using LORLATINIB ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 02 November, 2018
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer, progressed on: crizotinib + at least 1 other alk inhibitor for metastatic disease; Or alectinib, or ceritinib as first alk inhibitor for metastatic disease.; Treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive as detected by an fda-approved test
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10596107 | BAUSCH AND LOMB INC | Ophthalmic suspension composition |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Feb 22, 2022 |
Drugs and Companies using LOTEPREDNOL ETABONATE ingredient
Market Authorisation Date: 22 February, 2019
Treatment: Treatment of post-operative inflammation and pain following ocular surgery
Dosage: GEL;OPHTHALMIC
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10434103 | TAIHO ONCOLOGY | Crystal of 3,5-disubstituted benzene alkynyl compound |
Mar, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 30, 2027 |
Drugs and Companies using FUTIBATINIB ingredient
NCE-1 date: September, 2026
Market Authorisation Date: 30 September, 2022
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11304962 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) | |
US10471075 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) | |
US11154562 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) | |
US9844558 | COVIS | Methods of reducing risk of preterm birth |
May, 2036
(13 years from now) |
Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient
Market Authorisation Date: 03 February, 2011
Treatment: Reducing the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11246866 | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Jun, 2036
(13 years from now) | |
US11246866
(Pediatric) | ABBVIE INC | Solid pharmaceutical compositions for treating HCV |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 3, 2022 |
New Patient Population (NPP) | Apr 30, 2022 |
Orphan Drug Exclusivity (ODE) | Jun 10, 2028 |
New Dosing Schedule (D) | Sep 26, 2022 |
M | Apr 10, 2023 |
Pediatric Exclusivity (PED) | Feb 3, 2023 |
Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient
NCE-1 date: February, 2022
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11103517 | EPI HLTH | Pharmaceutical compositions for minocycline |
Apr, 2036
(13 years from now) |
Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient
Market Authorisation Date: 08 May, 2017
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: May, 2026
Market Authorisation Date: 13 May, 2022
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11338011 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
US11052126 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
US10695397 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
US10238709 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) | |
US11510963 | AMRYT | Method of treating diseases |
Feb, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Jun 26, 2023 |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Market Authorisation Date: 26 June, 2020
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10058536 | APGDI | Pharmaceutical composition containing mirabegron |
Mar, 2036
(13 years from now) | |
US10058536
(Pediatric) | APGDI | Pharmaceutical composition containing mirabegron |
Oct, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 25, 2024 |
Pediatric Exclusivity (PED) | Sep 25, 2024 |
Drugs and Companies using MIRABEGRON ingredient
Market Authorisation Date: 25 March, 2021
Treatment: Treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older by administration of an extended-release suspension formulation of mirabegron
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
New Product (NP) | Feb 26, 2023 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 30, 2024 |
New Indication (I) | Aug 5, 2025 |
Drugs and Companies using DAROLUTAMIDE ingredient
NCE-1 date: July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(13 years from now) | |
US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(13 years from now) | |
US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 27, 2023 |
Drugs and Companies using OBETICHOLIC ACID ingredient
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as monotherapy in adults unable to tolerate udca
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10266523 | SUN PHARM | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof |
Mar, 2036
(13 years from now) |
Drugs and Companies using SONIDEGIB PHOSPHATE ingredient
Market Authorisation Date: 24 July, 2015
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10835488 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) | |
US10076494 | DEXCEL PHARMA | Stable orally disintegrating pharmaceutical compositions |
Dec, 2036
(13 years from now) |
Drugs and Companies using OMEPRAZOLE ingredient
Market Authorisation Date: 05 July, 2017
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10456360 | IPSEN INC | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(13 years from now) | |
US10993914 | IPSEN INC | Stabilizing camptothecin pharmaceutical compositions |
Oct, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Oct 22, 2022 |
Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient
Market Authorisation Date: 22 October, 2015
Treatment: NA
Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10350170 | MYOVANT SCIENCES | Solid preparation |
Feb, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10682351 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) | |
US10537572 | ABBVIE INC | Methods of administering elagolix |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg elagolix while co-administering ketoconazole; Management of moderate to severe pain associated with endometriosis using 150mg elagolix while co-administering rifampin
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10172802 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(13 years from now) | |
US9707182 | SUN PHARM INDS INC | Oral pharmaceutical dosage forms of budesonide |
Sep, 2036
(13 years from now) |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 13 June, 2019
Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11020382 | GLOBAL BLOOD THERAPS | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 25, 2024 |
Drugs and Companies using VOXELOTOR ingredient
NCE-1 date: November, 2023
Market Authorisation Date: 17 December, 2021
Treatment: Treating sickle cell disease by administering 1500 mg of voxelotor orally once daily; Increasing hemoglobin to treat sickle cell disease by administering 1500 mg of voxelotor orally once daily
Dosage: TABLET, FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10569034 | TEVA BRANDED PHARM | Compliance monitoring module for a breath-actuated inhaler |
Aug, 2036
(13 years from now) |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Market Authorisation Date: 31 March, 2015
Treatment: NA
Dosage: POWDER, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10328037 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
US10548859 | HORIZON | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
US10905662 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
US10143665 | HORIZON | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
Pediatric Exclusivity (PED) | Feb 14, 2023 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 30 April, 2013
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10143665 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
US10328037 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
US10548859 | HORIZON PHARMA USA | Methods for storing Cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) | |
US10905662 | HORIZON PHARMA USA | Methods for storing cysteamine formulations and related methods of treatment |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 22, 2024 |
Pediatric Exclusivity (PED) | Feb 14, 2023 |
Drugs and Companies using CYSTEAMINE BITARTRATE ingredient
Market Authorisation Date: 14 February, 2020
Treatment: Management of nephropathic cystinosis by administering a total daily dose in two divided doses
Dosage: GRANULE, DELAYED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9951080 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpha]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10981923 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11186584 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11512092 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10344036 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-#a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-#carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10730883 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11198697 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10519164 | ABBVIE INC | Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10597400 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10995095 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10550126 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10981924 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US9963459 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-alpla]pyrrolo[2,3-e]-pyrazin-8-YL)-N-(2,2,2-Trifluoroethyl)pyrrol and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US11365198 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
US10202393 | ABBVIE INC | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 14, 2024 |
New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, or when use of those therapies are inadvisable
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11141540 | ADAMIS PHARMS CORP | Syringe devices |
Oct, 2036
(13 years from now) |
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 15 June, 2017
Treatment: A method for administering a therapeutic dose of epinephrine
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10925829 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
US9925138 | HANDA | Stable solid fingolimod dosage forms |
Jan, 2036
(12 years from now) | |
US10555902 | HANDA | Stable fingolimod dosage forms |
Jan, 2036
(12 years from now) |
Drugs and Companies using FINGOLIMOD LAURYL SULFATE ingredient
Market Authorisation Date: 23 December, 2021
Treatment: Treatment of multiple sclerosis in pediatric patients 10 years of age and older and weighing less than or equal to 40 kg
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
Orphan Drug Exclusivity (ODE) | Aug 25, 2028 |
New Indication (I) | May 25, 2025 |
Drugs and Companies using IVOSIDENIB ingredient
NCE-1 date: July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method for treating newly diagnosed aml characterized by the presence of a mutant allele of idh1 selected from r132h, r132c, r132l, r132v, r132s and r132gf by administering ivosidenib and azacitidine
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11266799 | IMPEL NEUROPHARMA | In-line nasal delivery device |
Nov, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 2, 2024 |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Market Authorisation Date: 02 September, 2021
Treatment: NA
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9802932 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) | |
US10730876 | DAIICHI SANKYO INC | Synthesis of a compound that modulates kinases |
May, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10189833 | DAIICHI SANKYO INC | Solid forms of a compound modulating kinases |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Aug 2, 2024 |
Orphan Drug Exclusivity (ODE) | Aug 2, 2026 |
Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient
NCE-1 date: August, 2023
Market Authorisation Date: 02 August, 2019
Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(13 years from now) | |
US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 21, 2022 |
Drugs and Companies using SELEXIPAG ingredient
Market Authorisation Date: 21 December, 2015
Treatment: Method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag; Method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11382926 | GILEAD SCIENCES INC | Methods for treating Arenaviridae and Coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
US10695361 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) | |
US11007208 | GILEAD SCIENCES INC | Methods for treating arenaviridae and coronaviridae virus infections |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Oct 22, 2025 |
New Patient Population (NPP) | Apr 25, 2025 |
New Dosing Schedule (D) | Jan 21, 2025 |
Drugs and Companies using REMDESIVIR ingredient
NCE-1 date: October, 2024
Market Authorisation Date: 22 October, 2020
Treatment: Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 28 days of age and 3 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 28 days of age and 3 kg); Treatment of coronavirus disease 2019 (covid-19) in adults and pediatric patients (at least 12 years of age and 40 kg) requiring hospitalization; Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (at least 12 years of age and 40 kg)
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10799505 | BAYER HEALTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 26, 2025 |
New Chemical Entity Exclusivity (NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10799505 | BAYER HLTHCARE | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 26, 2025 |
New Chemical Entity Exclusivity (NCE) | Nov 26, 2023 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 26 November, 2018
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(13 years from now) | |
US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Apr 26, 2027 |
Generating Antibiotic Incentives Now (GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: April, 2031
Market Authorisation Date: 26 April, 2022
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9907834 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) | |
US10646550 | BIOMARIN PHARM | Use of C-type natriuretic peptide variants to treat skeletal dysplasia |
Aug, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 19, 2026 |
Drugs and Companies using VOSORITIDE ingredient
NCE-1 date: November, 2025
Market Authorisation Date: 19 November, 2021
Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses
Dosage: POWDER;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11458108 | DERMAVANT SCI | NA |
May, 2036
(13 years from now) | |
US10195160 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(13 years from now) | |
US10426743 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: May, 2026
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11129896 | DARE | Topical formulations and treatments |
Sep, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Dec 7, 2024 |
Generating Antibiotic Incentives Now (GAIN) | Dec 7, 2029 |
Drugs and Companies using CLINDAMYCIN PHOSPHATE ingredient
Market Authorisation Date: 07 December, 2021
Treatment: Method of treating bacterial vaginosis by single dose administration of a clindamycin pharmaceutical gel formulation
Dosage: GEL;VAGINAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10392406 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10633397 | GENENTECH INC | Substituted polycyclic pyridone derivatives and prodrugs thereof |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Oct 16, 2022 |
New Chemical Entity Exclusivity (NCE) | Oct 24, 2023 |
Drugs and Companies using BALOXAVIR MARBOXIL ingredient
NCE-1 date: October, 2022
Market Authorisation Date: 24 October, 2018
Treatment: Method for treating influenza; Method for post-exposure prophylaxis of influenza
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10786500 | ASTELLAS | Stable pharmaceutical composition for oral administration |
Jul, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Nov 28, 2025 |
New Chemical Entity Exclusivity (NCE) | Nov 28, 2023 |
Drugs and Companies using GILTERITINIB FUMARATE ingredient
NCE-1 date: November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10646485 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
US10188644 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
US9737530 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) | |
US9968598 | COLLEGIUM PHARM INC | Process of making stable abuse-deterrent oral formulations |
Sep, 2036
(13 years from now) |
Drugs and Companies using OXYCODONE ingredient
Market Authorisation Date: 26 April, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9950125 | ANTARES PHARMA INC | Needle assisted jet injection administration of testosterone compositions |
Sep, 2036
(13 years from now) |
Drugs and Companies using TESTOSTERONE ENANTHATE ingredient
Market Authorisation Date: 28 September, 2018
Treatment: Method of administering testosterone enanthate subcutaneously
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10537554 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) | |
US11364224 | UPSHER SMITH LABS | Pharmaceutical composition for treating migraine |
Jan, 2036
(12 years from now) |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of migraine
Dosage: SOLUTION;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9844654 | ZUREX PHARMA | Medical skin applicator apparatus |
Apr, 2036
(13 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Apr 26, 2022 |
M | Jun 24, 2024 |
Drugs and Companies using ISOPROPYL ALCOHOL ingredient
Market Authorisation Date: 26 April, 2019
Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery
Dosage: SOLUTION;TOPICAL
Click on the highlighted region to filter.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US10844416 | BIOGEN INC. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
Jan, 2036
(12 years from now) | |
US11268119 | BIOGEN INC. | Copper supplementation for control of glycosylation in mammalian cell culture process |
Feb, 2036
(13 years from now) |
Ingredients: NATALIZUMAB
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
US10927342 | REGENERON PHARMACEUTICALS, INC. | Taurine supplemented cell culture medium and methods of use |
Aug, 2036
(13 years from now) | |
USD934069 | REGENERON PHARMACEUTICALS, INC. | Packaging |
Oct, 2036
(13 years from now) |
Ingredients: AFLIBERCEPT
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic